ArticleDiabetes technology & therapeutics2018
Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose Monitoring.
Article in Diabetes technology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Estimating plasma glucose with the FreeStyle Libre Pro continuous glucose monitor during oral glucose tolerance tests in youth without diabetes.Pediatric diabetes · 2019Trial
- Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study.Diabetes technology & therapeutics · 2018Trial
- Association Between Sedentary Behavior Patterns and Glycemic Outcomes in Women with Overweight and Obesity Under Free-Living Conditions.International journal of behavioral medicine · 2026Article
- Accuracy of FreeStyle Libre flash glucose monitoring in patients with type 2 diabetes who migrated from highlands to plains.World journal of diabetes · 2024Article
- Differences in glucose readings between the continuous glucose monitoring calibration free interstitial sensors versus capillary blood glucose monitoring by glucometer: An analysis of two cases.Metabolism open · 2024Article
- Clinical Performance Evaluation of Continuous Glucose Monitoring Systems: A Scoping Review and Recommendations for Reporting.Journal of diabetes science and technology · 2023Article
- Effectiveness of Using the FreeStyle LibreDiagnostics (Basel, Switzerland) · 2023Review
- Accuracy of Flash Glucose Monitoring in Hemodialysis Patients With and Without Diabetes Mellitus.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023Article
- Artificial intelligence for non-invasive glycaemic-events detection via ECG in a paediatric population: study protocol.Health and technology · 2023Article
- Technologies for Diabetes Self-Monitoring: A Scoping Review and Assessment Using the REASSURED Criteria.Journal of diabetes science and technology · 2022Article
- Variation of Mean Absolute Relative Differences of Continuous Glucose Monitoring Systems Throughout the Day.Journal of diabetes science and technology · 2022Article
- HbA1c and Glucose Management Indicator Discordance Associated with Obesity and Type 2 Diabetes in Intermittent Scanning Glucose Monitoring System.Biosensors · 2022Article
- Glycemic Metrics Derived From Intermittently Scanned Continuous Glucose Monitoring.Journal of diabetes science and technology · 2022Article
- Time in Specific Glucose Ranges, Glucose Management Indicator, and Glycemic Variability: Impact of Continuous Glucose Monitoring (CGM) System Model and Sensor on CGM Metrics.Journal of diabetes science and technology · 2021Article
- Extraction With Sweat-Sebum Emulsion as a New Test Method for Leachables in Patch-Based Medical Devices, Illustrated by Assessment of Isobornylacrylate (IBOA) in Diabetes Products.Journal of diabetes science and technology · 2021Article
- Diabetes Technology Meeting 2020.Journal of diabetes science and technology · 2021Article
- Comparative Accuracy Analysis of a Real-time and an Intermittent-Scanning Continuous Glucose Monitoring System.Journal of diabetes science and technology · 2021Article
- Proof of Concept for a New Raman-Based Prototype for Noninvasive Glucose Monitoring.Journal of diabetes science and technology · 2021Article
- Blood glucose and subcutaneous continuous glucose monitoring in critically ill horses: A pilot study.PloS one · 2021Article
- Clinical approaches to treat impaired awareness of hypoglycaemia.Therapeutic advances in endocrinology and metabolism · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, two systems for continuous tissue glucose monitoring (CGM) (Dexcom
methodsThe measurement performance of these two systems in comparison with a BGM system was analyzed in a 14-day study with 20 participants comprising study site visits, which included phases of induced rapid glucose changes, and home use phases. Performance analysis was mainly based on deviations between CGM readings and BGM results. Sensor-to-sensor precision was also analyzed.
resultsApproximately 25% of DG5 and FL results showed differences from BGM results exceeding 15 mg/dL or 15% (at glucose concentration below or above 100 mg/dL, respectively) at times of therapeutic decisions, and ∼5% of differences exceeded 30 mg/dL or 30%. Performance was different depending on the setting (study site visits, home use phases, and phases of induced rapid glucose changes). In consensus error grid (CEG) analysis, both systems showed >99.5% of results within the clinically acceptable zones A and B.
conclusionsIn this study, both systems showed deviations from blood glucose (BG) measurements, the current standard approach in diabetes therapy. Although a large percentage of results was found in CEG zones A and B, for approximately one in four therapeutic decisions, CGM and BG readings differed by at least 15 mg/dL or 15%. Such deviations should be taken into account when using CGM systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.